USD 14.83 billion, and by 2030 it will reach USD 55.78 billion, growing at a 15.86% CAGR during the forecast period. The rising demand for biologics is primarily responsible for the growth of the worldwide single-use bioprocessing market. Single-use containers are frequently used in the biomanufacturing and biopharmaceutical sectors for necessary liquid handling tasks. The main purpose of single-use bioprocessing equipment is to prevent hospital-acquired illnesses.
DriversThe biopharmaceutical industry’s expanding need heavily influences the market for single-use bioprocessing. Because single-use bioprocessing systems boost process efficiency and lower the expenses associated with sterilizing, cleaning, and maintaining steel bioreactors, most biopharmaceutical businesses are increasingly implementing this technology. The biopharmaceutical industry is also expanding quickly. Around 20% of the worldwide pharmaceutical market is made up solely of biopharmaceuticals. Cancer patients can also receive treatment with the help of single-use bioprocessing. Thus, the demand for single-use bioprocessing systems is greatly increased by biopharmaceuticals’ quick development. The rising geriatric population is also responsible for the growth of the single-use bioprocessing market. United Nations predicted that by 2050 nearly 1.5 billion population will be above 65.
RestraintsTherefore, significant worries regarding extractables and leachables coming from components of single-use bioprocessing systems may impede the overall industry expansion around the globe due to their possible effects on product quality and patient health.
OpportunityChina and India are the two countries in the Asia-Pacific area with the highest potential markets for single-use bioprocessing systems. This is due to favorable government policies, increased private investment, an aging population, a marked increase in outsourcing to developing Asian markets, and skilled labor in these countries.
By ProductIn 2022, the media bags and containers segment led the global single-use bioprocessing market. In the biopharmaceutical business, using media bags and containers offers inexpensive initial investment, reduced waste emission, and reduced operational costs. The single-use media bags and containers also offer durability and temperature resistance. As a result, the widespread usage of media bags and containers in the biopharmaceutical industry has contributed to the segment’s recent expansion.
By End-UserThe biopharmaceutical manufacturers segment was the biggest market in 2022 due to the industry’s rapid expansion. Additionally, more than 80% of biopharmaceutical firms have adopted single-use bioprocess systems because they are more affordable, effective, and dependable.
By ApplicationWith a notable revenue share in 2022, the filtration category ruled the global single-use bioprocessing market. Due to its effective filtering even at large scales, single-use bioprocess systems are becoming more and more popular infiltration. It is utilized for ultrafiltration, biomolecular polishing, and the removal of bioburden.
Regional AnalysisNorth America was the maximum market holder in 2022 in terms of the region due to the area’s rapidly expanding and developing biopharmaceutical sector. Additionally, the COVID-19 pandemic encouraged the government to invest significantly in the study and creation of COVID-19 vaccines, diagnostic tools, and medications. The Canadian government invested over US$ 160 million to create COVID-19 vaccines and medications in 2020. The main drivers of growth in the North American single-use bioprocess market are major companies, large-scale manufacturing facilities, rising disposable adoption, rising healthcare spending, and highly developed healthcare infrastructure. In addition, the region’s market for single-use bioprocess is rising exponentially due to its large number of contract manufacturers and its increasing use of disposables. The expanding biopharmaceutical market in countries like China, Japan, and India presents substantial growth possibilities for the Asia-Pacific region. As contract manufacturers expand quickly and biotechnology and pharmaceutical corporations increase their investments, Asia Pacific may eventually become the region where medications are manufactured.
- Getinge AB
- Sartorius Stedim Biotech S.A.
- Merck KGaA
- CESCO Bioengineering Co. Ltd.
- Danaher Corporation
- Thermo Fisher Scientific
- Eppendorf AG
- Distek, Inc.
- Able Corporation & Biott Corporation
- G&G Technologies
- PBS Biotech, Inc.
- ABEC, Inc.
- Solida Biotech GmbH
- Stobbe Pharma GmbH
- OmniBRx Biotechnologies
- Meissner Filtration Products, Inc.
- Bbi-Biotech GmbH
- Satake Chemical Equipment Mfg., Ltd.
- Celltainer Biotech
- Pierre Guerin
- Kuhner AG